In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...

Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine maker and an eczema therapy J&J acquired in a billion-dollar deal failed a ...

His job is to reimagine the future of drugmaking using that similarly trendy branch of computer science, artificial ...

Moderna Inc. (NASDAQ: MRNA) is advancing its vaccine portfolio, with regulatory submissions underway for its seasonal ...

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda ...

Researchers found that in mouse models (in a lab), SARS‑CoV‑2 mRNA vaccination triggered strong type I interferon signals, ...

The government’s announcement that GC Biopharma was selected as a Phase 1 (first-stage clinical trial) support company for an ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we rate it a hold.

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Arcellx Inc today and set a price target of $115.00. Claim 60% off TipRanks Premium for data-backed insights and research tools you need to ...